JP2013507131A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507131A5
JP2013507131A5 JP2012533375A JP2012533375A JP2013507131A5 JP 2013507131 A5 JP2013507131 A5 JP 2013507131A5 JP 2012533375 A JP2012533375 A JP 2012533375A JP 2012533375 A JP2012533375 A JP 2012533375A JP 2013507131 A5 JP2013507131 A5 JP 2013507131A5
Authority
JP
Japan
Prior art keywords
fusion antibody
acid sequence
amino acid
fusion
sulfatase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012533375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507131A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/052113 external-priority patent/WO2011044542A1/en
Publication of JP2013507131A publication Critical patent/JP2013507131A/ja
Publication of JP2013507131A5 publication Critical patent/JP2013507131A5/ja
Withdrawn legal-status Critical Current

Links

JP2012533375A 2009-10-09 2010-10-08 Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物 Withdrawn JP2013507131A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25037809P 2009-10-09 2009-10-09
US61/250,378 2009-10-09
US25604909P 2009-10-29 2009-10-29
US61/256,049 2009-10-29
PCT/US2010/052113 WO2011044542A1 (en) 2009-10-09 2010-10-08 Methods and compositions for increasing iduronate 2-sulfatase activity in the cns

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016014716A Division JP2016155805A (ja) 2009-10-09 2016-01-28 Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物

Publications (2)

Publication Number Publication Date
JP2013507131A JP2013507131A (ja) 2013-03-04
JP2013507131A5 true JP2013507131A5 (enExample) 2013-07-25

Family

ID=43857180

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012533375A Withdrawn JP2013507131A (ja) 2009-10-09 2010-10-08 Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物
JP2016014716A Pending JP2016155805A (ja) 2009-10-09 2016-01-28 Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物
JP2018089998A Pending JP2018154629A (ja) 2009-10-09 2018-05-08 Cnsにおけるイズロン酸 2−スルファターゼ活性を増加させるための方法および組成物
JP2020167101A Pending JP2021008488A (ja) 2009-10-09 2020-10-01 Cnsにおけるイズロン酸 2−スルファターゼ活性を増加させるための方法および組成物
JP2022205808A Pending JP2023033321A (ja) 2009-10-09 2022-12-22 Cnsにおけるイズロン酸 2-スルファターゼ活性を増加させるための方法および組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016014716A Pending JP2016155805A (ja) 2009-10-09 2016-01-28 Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物
JP2018089998A Pending JP2018154629A (ja) 2009-10-09 2018-05-08 Cnsにおけるイズロン酸 2−スルファターゼ活性を増加させるための方法および組成物
JP2020167101A Pending JP2021008488A (ja) 2009-10-09 2020-10-01 Cnsにおけるイズロン酸 2−スルファターゼ活性を増加させるための方法および組成物
JP2022205808A Pending JP2023033321A (ja) 2009-10-09 2022-12-22 Cnsにおけるイズロン酸 2-スルファターゼ活性を増加させるための方法および組成物

Country Status (11)

Country Link
US (5) US8834874B2 (enExample)
EP (3) EP3533467B1 (enExample)
JP (5) JP2013507131A (enExample)
DK (1) DK2485761T3 (enExample)
ES (1) ES2725200T3 (enExample)
HR (1) HRP20190690T1 (enExample)
HU (1) HUE044865T2 (enExample)
PL (1) PL2485761T3 (enExample)
PT (1) PT2485761T (enExample)
SI (1) SI2485761T1 (enExample)
WO (1) WO2011044542A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1463512B1 (en) 2002-01-11 2014-05-28 biOasis Technologies Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2008022349A2 (en) * 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
CA2694762A1 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
EP2408474B1 (en) * 2009-03-18 2019-06-26 Armagen, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
HUE044865T2 (hu) * 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
BR112014002219A2 (pt) 2011-07-05 2018-08-07 Bioasis Technologies Inc conjugados anticorpo p97 e métodos de sua utilização
ES2983576T3 (es) 2011-12-02 2024-10-23 Armagen Inc Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
BR112014024358A8 (pt) 2012-03-30 2018-01-23 Shire Human Genetic Therapies administração subcutânea de iduronato-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
CA2880162C (en) 2012-07-31 2023-04-04 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
WO2014082184A1 (en) * 2012-11-30 2014-06-05 Angiochem Inc. Targeted iduronate-2-sulfatase compounds
WO2014110368A1 (en) 2013-01-11 2014-07-17 The California Institute For Biomedical Research Bovine fusion antibodies
CA2906003C (en) 2013-03-13 2021-07-06 Bioasis Technologies Inc. Fragments of p97 and uses thereof
CN105814074B (zh) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
EP3730516A1 (en) * 2013-07-22 2020-10-28 Armagen, Inc. Methods and compositions for increasing enzyme activity in the cns
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
EP3450557A1 (en) 2013-12-25 2019-03-06 JCR Pharmaceuticals Co., Ltd. Novel anti-transferrin receptor antibody that passes through blood-brain barrier
WO2015117121A1 (en) 2014-02-03 2015-08-06 Bioasis Technologies, Inc. P97 fusion proteins
EP3107562B1 (en) 2014-02-19 2019-09-18 Bioasis Technologies Inc. P97-ids fusion proteins
MX2016011561A (es) * 2014-03-06 2017-04-13 Nat Res Council Canada Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos.
PE20170088A1 (es) * 2014-03-06 2017-03-09 Nat Res Council Canada Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
UA120047C2 (uk) * 2014-03-06 2019-09-25 Нешнл Рісеч Каунсіл Оф Канада Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r)
DE102014205817A1 (de) * 2014-03-28 2015-10-01 Aktiebolaget Skf Wälzlagerkäfig und Verfahren zur Montage eines Wälzlagerkäfigs
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
AU2016283344B2 (en) 2015-06-24 2022-08-04 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing BDNF
EA039366B1 (ru) * 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
US20180243370A1 (en) 2015-09-14 2018-08-30 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
RU2673038C2 (ru) * 2016-01-18 2018-11-21 ООО "Международный Биотехнологический Центр "Генериум" Лекарственное средство на основе бифункционального антитела для лечения мукополисахаридоза II типа
WO2018038243A1 (ja) * 2016-08-25 2018-03-01 Jcrファーマ株式会社 抗体融合蛋白質の製造方法
EP3561058B1 (en) 2016-12-26 2025-07-23 JCR Pharmaceuticals Co., Ltd. Fusion protein including bdnf
JP6956741B2 (ja) 2016-12-26 2021-11-02 Jcrファーマ株式会社 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
WO2019143761A1 (en) * 2018-01-17 2019-07-25 Children's Hospital Medical Center Compositions and methods for treatment of hunter's syndrome
WO2019204912A1 (en) * 2018-04-24 2019-10-31 National Research Council Of Canada Blood-brain barrier transmigrating therapeutic compounds and uses thereof
EP3833689A4 (en) * 2018-08-07 2022-05-25 Armagen, Inc. METHODS AND COMPOSITIONS FOR INCREASING THE ACTIVITY IN THE CENTRAL NERVOUS SYSTEM OF HEXOSAMINIDASE A, ACID SPHINGOMYELINASE AND PALMITOYL-PROTEIN THIOESTERASE 1
KR102692543B1 (ko) * 2018-10-26 2024-08-07 재단법인 목암생명과학연구소 Ids를 포함하는 융합 단백질 및 이의 용도
US20220002688A1 (en) 2018-12-20 2022-01-06 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
US20220184186A1 (en) * 2019-04-03 2022-06-16 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
EP4265715A4 (en) 2021-01-12 2024-11-27 JCR Pharmaceuticals Co., Ltd. Nucleic acid molecule containing incorporated gene encoding fused protein of ligand and protein having physiological activity
CN118019768A (zh) * 2021-08-18 2024-05-10 吉尼瑞姆股份公司 治疗酶的靶向递送
CA3238914A1 (en) 2021-11-19 2023-05-25 Jcr Pharmaceuticals Co., Ltd. Peptide having affinity for human transferrin receptor
EP4455290A4 (en) 2021-12-28 2025-11-26 Japan Chem Res Fusion protein of an anti-transferrin receptor antibody and a bioactive protein for safe gene therapy
IL322412A (en) 2023-02-07 2025-09-01 Japan Chem Res A peptide with high affinity for the human transferrin receptor
WO2024177535A1 (ru) * 2023-02-21 2024-08-29 Акционерное общество "ГЕНЕРИУМ" Фармацевтическая композиция и способ профилактики и лечения недостаточности лизосомального фермента у субъекта, имеющего мукополисахаридоз ii типа

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
TW279133B (enExample) 1990-12-13 1996-06-21 Elan Med Tech
US6060069A (en) 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
ATE188708T1 (de) 1991-08-21 2000-01-15 Novartis Ag Antikörperderivate
MX9205293A (es) 1991-09-20 1993-05-01 Syntex Sinergen Neuroscience J Factores neurotrofico derivado del glial
JPH06228199A (ja) 1992-11-27 1994-08-16 Takeda Chem Ind Ltd 血液脳関門通過可能なペプチド結合体
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US6195608B1 (en) 1993-05-28 2001-02-27 Lucent Technologies Inc. Acoustic highway monitor
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
EP0706799B1 (en) 1994-09-16 2001-11-14 MERCK PATENT GmbH Immunoconjugates II
US5656284A (en) 1995-04-24 1997-08-12 Balkin; Michael S. Oral transmucosal delivery tablet and method of making it
AU6163196A (en) 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
DE69630798T2 (de) 1995-09-19 2004-09-23 Fujisawa Pharmaceutical Co., Ltd. Aerosolzusammensetzungen
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US5837231A (en) 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
US6030803A (en) 1996-07-16 2000-02-29 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgeszonheid En Cultuur Dibenzodihydropyridinecarboxylic esters and their use in chemiluminescent assay methods
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
AU8269898A (en) 1997-06-27 1999-01-19 Regents Of The University Of California, The Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
WO1999000951A1 (en) 1997-06-30 1999-01-07 Motorola Inc. Circuit and packet switched network interconnection
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6016800A (en) 1997-10-24 2000-01-25 Century; Theodore J. Intrapulmonary aerosolizer
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
DE69839969D1 (de) 1997-12-11 2008-10-16 Alza Corp Vorrichtung zur verbesserung des transdermalen flusses von medikamenten
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
JP4113670B2 (ja) 1998-06-22 2008-07-09 イムノメディクス, インコーポレイテッド プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用
US6348210B1 (en) 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US6284262B1 (en) 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
US7214658B2 (en) 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
WO2000051621A1 (en) 1999-03-05 2000-09-08 Epigenesis Pharmaceuticals, Inc. Method for validating/invalidating target(s) and pathways
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
DK1409654T3 (da) 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
AU6607100A (en) 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
JP3589912B2 (ja) 1999-09-03 2004-11-17 泰久 福井 ホスファチジルイノシトール−3,4−二リン酸を認識するモノクローナル抗体
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6195605B1 (en) 1999-09-29 2001-02-27 Bmi Technologies Inc. Impact monitor
US6585971B1 (en) 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
US6248262B1 (en) 2000-02-03 2001-06-19 General Electric Company Carbon-reinforced thermoplastic resin composition and articles made from same
CA2401645A1 (en) 2000-02-29 2001-09-07 Lexicon Genetics Incorporated Novel human transporter proteins and polynucleotides encoding the same
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US6696274B2 (en) 2000-05-03 2004-02-24 Supratek Pharma, Inc. Ligand for enhancing oral and CNS delivery of biological agents
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
WO2002055736A2 (en) 2000-12-04 2002-07-18 Univ California Antisense imaging of gene expression of the brain in vivo
KR100896971B1 (ko) 2001-02-02 2009-05-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 프락토피라노오스 설파메이트 및 에리트로포이에틴을포함하는 신경계 기능장애 치료법
RU2003125637A (ru) 2001-02-06 2005-03-10 Мерк Патент ГмбХ (DE) Модифицированный нейтрофический фактор выделенный из мозга человека (bdnf) с уменьшенной иммуногенностью
US8163289B2 (en) 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
ES2391905T3 (es) 2001-08-17 2012-11-30 Washington University Método de ensayo para la enfermedad de alzheimer
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
WO2003032913A2 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
EP1514106A4 (en) 2002-05-29 2007-05-09 Zystor Therapeutics Inc TARGETED THERAPEUTIC PROTEINS
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
ZA200506159B (en) * 2003-02-10 2006-10-25 Elan Pharm Inc Immunoglobulin formulation and method of preparation thereof
US8227212B2 (en) * 2003-02-11 2012-07-24 Shire Human Genetic Therapies, Inc. Cell that expresses a sulfatase and a formylglycine generating enzyme
DK1610820T4 (da) 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
WO2004108071A2 (en) 2003-06-05 2004-12-16 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
US7112299B2 (en) 2003-07-09 2006-09-26 Michael Merrick Systems and methods for fabricating composite fiberglass laminate articles
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
EP1548031A1 (en) 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Nature-identical erythropoietin
NZ548871A (en) 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
ES2344302T3 (es) 2004-02-10 2010-08-24 Zystor Therapeutics , Inc. Alfa glucosidasa acida y fragmentos de la misma.
EP1713502A1 (de) * 2004-02-12 2006-10-25 MERCK PATENT GmbH Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1841455A1 (en) 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
US7932032B2 (en) 2005-05-02 2011-04-26 Toray Industries, Inc. Method for diagnosing esophageal cancer
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
WO2007022416A2 (en) 2005-08-18 2007-02-22 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
WO2007044468A2 (en) 2005-10-05 2007-04-19 The Cbr Institute For Biomedical Research, Inc. Method to treat flavivirus infection with sirna
US8124095B2 (en) 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8142781B2 (en) 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
JP4860702B2 (ja) 2005-10-21 2012-01-25 エフ.ホフマン−ラ ロシュ アーゲー ポリペプチドのリコンビナント発現のための方法
IL193282A (en) 2006-02-06 2013-04-30 Yeda Res & Dev Chimeric protein of therapeutic enzyme and granulocyte-stimulating factor for treatment of lysosomal storage diseases
CA2641070C (en) 2006-02-06 2017-01-03 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
US7981417B2 (en) 2006-06-07 2011-07-19 Wisconsin Alumni Research Foundation Blood-brain barrier targeting anti-bodies
EP2029621A2 (en) 2006-06-07 2009-03-04 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
US9388425B2 (en) 2006-10-20 2016-07-12 Trustees Of Boston University Tunable genetic switch for regulating gene expression
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
EP2167115A2 (en) 2007-06-15 2010-03-31 University Of Zurich Treatment for alzheimer's disease
CA2694762A1 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
WO2009070597A2 (en) 2007-11-26 2009-06-04 Armagen Technologies, Inc. Fusion proteins for delivery of gdnf to the cns
US20110223147A1 (en) 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US8632774B2 (en) 2008-07-02 2014-01-21 Emergent Product Development Seattle, Llc Antagonists of IL-6
US20100077498A1 (en) 2008-09-11 2010-03-25 Pardridge William M Compositions and methods for blood-brain barrier delivery in the mouse
US20100098693A1 (en) 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
EP2408474B1 (en) 2009-03-18 2019-06-26 Armagen, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
WO2010141932A1 (en) 2009-06-05 2010-12-09 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
ES2618894T3 (es) 2009-06-24 2017-06-22 Curna, Inc. Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
HUE044865T2 (hu) 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
HRP20191924T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
US20110318327A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
PT3626258T (pt) 2010-06-25 2021-10-19 Shire Human Genetic Therapies Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase
MX2013000320A (es) 2010-06-25 2013-06-05 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa.
EA034333B1 (ru) 2010-11-30 2020-01-29 Дженентек, Инк. Варианты антитела для переноса соединения через гематоэнцефалический барьер
WO2012085622A1 (en) 2010-12-22 2012-06-28 Fondazione Telethon Therapeutic strategies to treat cns pathology in mucopolysaccharidoses
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
US20130039888A1 (en) 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
US9845327B2 (en) 2011-06-22 2017-12-19 The General Hospital Corporation Treatment of proteinopathies
WO2013052915A2 (en) 2011-10-05 2013-04-11 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
JP6329483B2 (ja) 2011-10-12 2018-05-23 シナジェバ・バイオファーマ・コーポレイションSynageva Biopharma Corp. 組換えヒトnagluタンパク質およびその利用
ES2983576T3 (es) 2011-12-02 2024-10-23 Armagen Inc Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
WO2013181454A1 (en) 2012-05-30 2013-12-05 Biostrategies LC Plant lectins as carriers of associated drug substances into animal and human cells
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
EP2880057A4 (en) 2012-08-02 2016-03-23 Jn Biosciences Llc MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL
CA2888628A1 (en) 2012-10-19 2014-04-24 Tokushima University Novel high functional enzyme having modified substrate specificity of human beta-hexosaminidase b and exhibiting protease resistance
JP6083219B2 (ja) 2012-12-06 2017-02-22 富士通セミコンダクター株式会社 プラズマフラッドガン及びイオン注入装置
US20140354655A1 (en) 2013-06-04 2014-12-04 Qualcomm Mems Technologies, Inc. Reducing floating node leakage current with a feedback transistor
US10906981B2 (en) 2013-07-19 2021-02-02 The Regents Of The University Of California Compositions and methods related to structures that cross the blood brain barrier
EP3730516A1 (en) 2013-07-22 2020-10-28 Armagen, Inc. Methods and compositions for increasing enzyme activity in the cns
PL3119892T3 (pl) 2014-03-17 2021-11-29 The Hospital For Sick Children Warianty białka beta-heksozaminidazy oraz związane z nimi sposoby do leczenia gangliozydoz gm2
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP6956741B2 (ja) 2016-12-26 2021-11-02 Jcrファーマ株式会社 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体
KR102471458B1 (ko) 2016-12-28 2022-11-25 제이씨알 파마 가부시키가이샤 동결건조 제제
EP3833689A4 (en) 2018-08-07 2022-05-25 Armagen, Inc. METHODS AND COMPOSITIONS FOR INCREASING THE ACTIVITY IN THE CENTRAL NERVOUS SYSTEM OF HEXOSAMINIDASE A, ACID SPHINGOMYELINASE AND PALMITOYL-PROTEIN THIOESTERASE 1
US20220002688A1 (en) 2018-12-20 2022-01-06 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
EP3908611A4 (en) 2019-01-08 2022-10-12 Armagen, Inc. Methods and compositions for increasing galactosidase beta-1 activity in the cns

Similar Documents

Publication Publication Date Title
JP2013507131A5 (enExample)
JP2010534723A5 (enExample)
JP7195142B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP6383122B2 (ja) C5関連疾患の治療または予防用の医薬組成物およびc5関連疾患を治療または予防するための方法
CN104684552B (zh) 组合及其用途
JP2016525545A5 (enExample)
US20130078216A1 (en) Liver targeting molecules
JP2008515446A5 (enExample)
JP2017529059A5 (enExample)
JP2013135695A5 (enExample)
JP6672516B2 (ja) C5関連疾患の治療または予防用の医薬組成物およびc5関連疾患を治療または予防するための方法
JP2014533700A5 (enExample)
JP2010533181A5 (enExample)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
JP2012525128A5 (enExample)
AU2015379642B2 (en) Treatment of autoimmune disorders with CD154 antibodies
JP2018535948A5 (enExample)
TWI500629B (zh) 介白素-6抗體及其用途
RU2012139829A (ru) АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8
JP2014534956A5 (enExample)
CN111787981A (zh) 改变身体组成的方法
JP2015096065A5 (enExample)
WO2023116751A1 (zh) 抗人血管生成素3纳米抗体及其应用
JP2017524675A5 (enExample)
JP2014501490A5 (enExample)